Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Update

Genenta Science S.p.A. (NASDAQ:GNTA) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 3,100 shares, a growth of 121.4% from the November 30th total of 1,400 shares. Based on an average daily trading volume, of 13,600 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Genenta Science in a report on Wednesday, October 2nd.

Institutional Trading of Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. purchased a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science as of its most recent filing with the SEC. 15.13% of the stock is owned by hedge funds and other institutional investors.

Genenta Science Trading Down 4.1 %

Shares of GNTA stock traded down $0.05 during trading hours on Friday, hitting $4.94. 605 shares of the company were exchanged, compared to its average volume of 9,665. The firm has a fifty day simple moving average of $5.11 and a 200 day simple moving average of $4.41. Genenta Science has a 52-week low of $2.20 and a 52-week high of $7.28.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.